Mark O’Connor @AstraZeneca about learnings from PARP inhibitors, the only example of a synthetic lethality scenario turned into clinical benefit. Elucidating sensitivity profiles beyond mutBRCA, validating the trapping hypothesis, not all inhibitors were created equally. #AACR26 https://t.co/hFQvsoIEn2